William Blair Raises Earnings Estimates for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Research analysts at William Blair raised their FY2028 earnings per share (EPS) estimates for Genmab A/S in a report issued on Monday, March 10th. William Blair analyst M. Phipps now forecasts that the company will post earnings of $4.06 per share for the year, up from their prior estimate of $4.02. William Blair has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

A number of other brokerages also recently issued reports on GMAB. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Down 0.2 %

GMAB stock opened at $20.21 on Wednesday. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The firm has a market cap of $13.37 billion, a P/E ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The company’s 50-day simple moving average is $21.28 and its 200-day simple moving average is $22.52.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC increased its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC raised its stake in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.